Cape Investment Advisory’s Protagonist Therapeutics PTGX Stock Holding History

Cape Investment Advisory’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.3K	Buy	+73	New	+$10.4K	﹤0.01%	861

Other funds holding PTGX

Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Cape Investment Advisory's PTGX Position: Q3 2026 in Review

Cape Investment Advisory opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 73 shares worth $10.3K. The stake represents ﹤0.01% of the portfolio and ranks #861 among its holdings.

14 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

Cape Investment Advisory held 73 shares of Protagonist Therapeutics worth $10.3K as of Q3 2026.
Protagonist Therapeutics was a new Cape Investment Advisory position in Q3 2026.
Protagonist Therapeutics made up ﹤0.01% of Cape Investment Advisory's portfolio in Q3 2026, its #861 holding.
14 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Cape Investment Advisory's 13F filing for Q3 2026, filed 13 Oct 2026.